Threshold analysis
| Strategy | Current wholesale cost | Cost-effective cost |
|---|---|---|
| Infliximab 5 mg/kg every 8 weeks* | $1114 | – |
| Adalimumab 40 mg EOW | $1748 | ≤$1156 |
| Vedolizumab 300 mg every 8 weeks | $5788 | ≤$2537 |
*Infliximab administration costs exceeding $1974 represents a cut-off price at which it becomes a cost-ineffective strategy.
EOW, every other week.